Navigation Links
Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
Date:6/2/2008

ed for use in patients with severe problems digesting food or those who have severe disease of the stomach or kidney.

When BYETTA is used with a medicine that contains a sulfonylurea, hypoglycemia (low blood sugar) is a possible side effect. To reduce this possibility, the dose of sulfonylurea medicine may need to be reduced while using BYETTA. Other common side effects with BYETTA include nausea, vomiting, diarrhea, dizziness, headache, feeling jittery, and acid stomach. Nausea is most common when first starting BYETTA, but decreases over time in most patients.

If patients experience the following severe and persistent symptoms (alone or in combination): abdominal pain, nausea, vomiting, or diarrhea, they should talk to their healthcare provider because these symptoms could be signs of serious medical conditions. BYETTA may reduce appetite, the amount of food eaten, and body weight. No changes in dose are needed for these side effects. These are not all of the side effects from use of BYETTA. A healthcare provider should be consulted about any side effect that is bothersome or does not go away.

For full prescribing information, visit http://www.BYETTA.com.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 2,000 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com. '/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
2. Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
3. Amylin Pharmaceuticals to Present at Baird Growth Stock Conference
4. Amylin Pharmaceuticals to Present at Bank of America Healthcare Conference
5. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
6. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
7. Amylin Pharmaceuticals to Webcast First Quarter Results
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
10. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
11. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... December 18, 2014 LayerBio is an ... and wound care. The National Eye Institute (NEI) at ... a Phase I SBIR grant to develop a drug-eluting ... the most common cause of vision loss in people ... worldwide. According to Dr. Ken Mandell, LayerBio’s Founder and ...
(Date:12/19/2014)... Boston, MA (PRWEB) December 18, 2014 ... software, announced the appointment of Siri Bryant as the ... the new Director of Core Implementations. These two new ... provide outstanding customer service by ensuring that iLab continues ... , “In the last four years, iLab has been ...
(Date:12/19/2014)... With only 2 weeks left of ... Sartorius Biohit products . The product specials include Buy ... Pipette Trade-in Program, and free pipette tips. , Sartorius ... the world. They are ideal for lab technicians performing ... ,     Full volume range of 0.1 uL to ...
(Date:12/19/2014)... 2014   ISN has released its third ... publication series. With data aggregated from over ... 2013 within its online contractor management platform, ISNetworld, this ... indicator (KPI) statistics. The ... publication is available in two industry specific volumes: ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3
... , QUINCY, Mass., Dec. 7 Myriant ... developer and manufacturer of renewable biochemicals, has been selected by ... $50 million for its planned biobased Succinic Acid facility in ... won funding or loan guarantees, Myriant was the only award ...
... , , Response Rate Increases to 41% ... All Evaluable Patients , QUEBEC CITY, Dec. 7 /PRNewswire-FirstCall/ - ... "Company"), a global biopharmaceutical company focused on endocrine therapy and ... ( KERX) reported updated efficacy and safety data as well ...
... , ... customizing, manufacturing, and marketing enzymes for the,chemical industry, announced today ... CEO of the Company. Going forward, EUCODIS Bioscience,sole focus will ... experience in commercial enzyme development and,on its proven technology of ...
Cached Biology Technology:Myriant Technologies LLC Selected for $50 Million Award for Succinic Acid Biorefinery Project 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2
(Date:11/21/2014)... 2014 C-Labs LLC, a leading provider of ... (IoT), today announced the appointment of John Traynor ... a strategic advisor to the firm, Mr. Traynor will ... is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. Photo ...
(Date:11/18/2014)... , Nov. 17, 2014   ... and EMC collaborate to develop The Partners Data ... , The Partners Data Lake will allow researcher ... improve diagnostics, treatment and the lives of patients ... research and clinical activities across the Partners system, ...
(Date:11/15/2014)... 13, 2014  While we may still be a few ... in "Star Trek" to gain instant access to all that ... with smartphones and tablets for monitoring and measuring our health ... This may seem a tad Orwellian to some, but a ... of these technological opportunities into their healthcare regime. ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... could release at least one billion Euro in cash ... The claim has been made following an international study ... companies in monetary terms. Entitled Sustainable Value Creation by ... European research team including academics from Queen,s University Management ...
... FEBRUARY 23, 2010 Scientists seeking answers to the complex ... receptors triggers preterm labor, study how genetics and the ... D can suppress factors that make some women more ... support of the March of Dimes. The March ...
... Researchers at the University of Illinois at Chicago Institute ... federal grant to determine whether or not TV food advertising ... project, funded by the National Cancer Institute, is unique because ... the amount of time that children watch TV. "A ...
Cached Biology News:Study highlights sustainable footprint of chemical companies 2Study highlights sustainable footprint of chemical companies 3March of Dimes provides $2.6 million in new funding for preterm birth research 2Do TV ads affect children's diet, obesity? 2
Rad51, N-terminal...
Phospho-mu-Opioid Receptor (Ser375) Antibody...
Rabbit polyclonal to WWOX8 ( Abpromise for all tested applications). entrezGeneID: 51741 SwissProtID: Q9NZC7-8...
... Extraction Reagent extracts cytosolic proteins ... while preserving their phosphorylation state. ... the CytoBuster Protein Extraction reagent, ... is compatible with Western blotting, ...
Biology Products: